1.
J Investig Allergol Clin Immunol
; 31(3): 265-267, 2021 Jun 22.
Article
in English
| MEDLINE
| ID: mdl-32856592
Subject(s)
Adenocarcinoma/drug therapy , Anaphylaxis/prevention & control , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Bevacizumab/therapeutic use , Desensitization, Immunologic/methods , Drug Hypersensitivity/therapy , Drug-Related Side Effects and Adverse Reactions/prevention & control , Lung Neoplasms/drug therapy , Adenocarcinoma/complications , Anaphylaxis/etiology , Antibodies, Monoclonal, Humanized/adverse effects , Antineoplastic Agents, Immunological/adverse effects , Bevacizumab/adverse effects , Drug Hypersensitivity/complications , Humans , Lung Neoplasms/complications , Male , Middle Aged , Severity of Illness Index , Treatment Outcome
2.
J. investig. allergol. clin. immunol
; 31(3): 265-267, 2021. tab
Article
in English
| IBECS
| ID: ibc-215213